Immuneering Corp. (IMRX)
4.61
-0.17
(-3.56%)
USD |
NASDAQ |
Sep 09, 14:39
Immuneering PS Ratio
PS Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical PS Ratio Data
| Date | Value |
|---|---|
| December 29, 2023 | 407053.3 |
| December 28, 2023 | 431974.9 |
| December 27, 2023 | 409822.4 |
| December 26, 2023 | 414252.9 |
| December 22, 2023 | 387669.8 |
| December 21, 2023 | 386562.2 |
| December 20, 2023 | 371055.4 |
| December 19, 2023 | 430867.3 |
| December 18, 2023 | 439174.5 |
| December 15, 2023 | 443051.2 |
| December 14, 2023 | 428098.2 |
| December 13, 2023 | 377147.3 |
| December 12, 2023 | 361640.5 |
| December 11, 2023 | 389331.2 |
| December 08, 2023 | 408160.9 |
| December 07, 2023 | 452466.0 |
| December 06, 2023 | 456896.6 |
| December 05, 2023 | 467419.0 |
| December 04, 2023 | 458558.0 |
| December 01, 2023 | 458004.2 |
| November 30, 2023 | 363302.0 |
| November 29, 2023 | 363855.8 |
| November 28, 2023 | 399299.9 |
| November 27, 2023 | 436959.2 |
| November 24, 2023 | 426436.8 |
| Date | Value |
|---|---|
| November 22, 2023 | 413145.2 |
| November 21, 2023 | 387669.8 |
| November 20, 2023 | 309028.2 |
| November 17, 2023 | 310135.8 |
| November 16, 2023 | 284660.4 |
| November 15, 2023 | 292413.8 |
| November 14, 2023 | 291583.1 |
| November 13, 2023 | 268046.0 |
| November 10, 2023 | 287152.6 |
| November 09, 2023 | 287983.3 |
| November 08, 2023 | 326750.3 |
| November 07, 2023 | 332288.4 |
| November 06, 2023 | 332288.4 |
| November 03, 2023 | 332288.4 |
| November 02, 2023 | 332288.4 |
| November 01, 2023 | 358871.5 |
| October 31, 2023 | 389331.2 |
| October 30, 2023 | 330073.1 |
| October 27, 2023 | 276907.0 |
| October 26, 2023 | 296844.3 |
| October 25, 2023 | 305151.5 |
| October 24, 2023 | 304043.9 |
| October 23, 2023 | 314566.4 |
| October 20, 2023 | 325642.6 |
| October 19, 2023 | 332288.4 |
Price to Sales Ratio Definition
The Price to Sales Ratio (PS Ratio) is calculated by taking the stock price / revenue per share (ttm). This metric is considered a valuation metric that confirms whether the sales of a company justifies the stock price. There isn't necesarily an optimum PS ratio, since different industries will have different ranges of PS Ratios. Because of this, PS Ratio is great to evaluate from a relative standpoint with other similar companies. PS Ratio might also be a handy metric for companies that are not profitable yet, since they might be valued moreso by their overall sales and potential of becoming profitable in the future.
PS Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
PS Ratio Benchmarks
| Regeneron Pharmaceuticals, Inc. | 5.539 |
| ACADIA Pharmaceuticals, Inc. | 4.204 |
| Alnylam Pharmaceuticals, Inc. | 7.279 |
| Anika Therapeutics, Inc. | 2.451 |
| Savara, Inc. | -- |
PS Ratio Related Metrics
| Price to Book Value | 1.564 |
| Price | 4.61 |
| Earnings Yield | -22.38% |
| Market Cap | 298.26M |